Successful foscarnet therapy for mucocutaneous infection with herpes simplex virus in a recipient after unrelated bone marrow transplantation.
Bone Marrow Transplant
; 18(6): 1185-8, 1996 Dec.
Article
en En
| MEDLINE
| ID: mdl-8971394
ABSTRACT
A 36-year-old Japanese man who received an unrelated bone marrow transplant (BMT) developed severe mucocutaneous infection with herpes simplex virus (HSV) type 1 during oral acyclovir prophylaxis. The lesions progressed despite treatment with intravenous acyclovir and vidarabine. The HSV isolates were sensitive acyclovir, vidarabine and foscarnet in vitro, but peripheral CD3- or CD19-positive cells were barely detectable even 4 months after transplant. A 12-day course of treatment with foscarnet led to a rapid improvement. Foscarnet therapy should be considered for all severe HSV infections following BMT, regardless of whether or not the HSV isolates are sensitive to acyclovir.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Antivirales
/
Estomatitis Herpética
/
Trasplante de Médula Ósea
/
Foscarnet
/
Herpes Labial
Límite:
Adult
/
Humans
/
Male
Idioma:
En
Año:
1996
Tipo del documento:
Article